Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: Application of factorial design approach

Drug Delivery

Volumn 20, Issue 1, 2013, Pages 47-56

  Pardeshi, Chandrakantsing V ^a   Rajput, Pravin V ^a   Belgamwar, Veena S ^a   Tekade, Avinash R ^a   Surana, Sanjay J ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Emulsification solvent diffusion technique; Factorial design; Nasal delivery; Parkinson's disease; Ropinirole hydrochloride; Solid lipid nanoparticles

Indexed keywords

POLOXAMER; ROPINIROLE; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; EMULSION; ENCAPSULATION; FACTORIAL DESIGN; FREEZE DRYING; HISTOPATHOLOGY; MOUSE; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIPARKINSON AGENTS; DRUG CARRIERS; INDOLES; LIPIDS; MALE; MICE; NANOPARTICLES; NASAL MUCOSA; ORGAN CULTURE TECHNIQUES; SHEEP; SURFACE PROPERTIES;

EID: 84872243324     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.752421     Document Type: Article

References (28)

1. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. (2006). Freezedrying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 58:1688-713.
2. Belgamwar VS, Patel HS, Joshi AS, et al. (2011). Design and development of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting. Drug Deliv 18:353-60.
3. Chalikwar SS, Belgamwar VS, Talele VR, et al. (2012). Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surf B: Biointerfaces 97:109-16.
4. Fukuzaki K, Kamenosono T, Nagata R. (2000). Effects of ropinirole on various Parkinsonian models in mice, rats, and cynomolgus monkeys. Pharmacol Biochem Behav 65:503-8.
5. Heurtault B, Saulnier P, Pech B, et al. (2003). Physico-chemical stability of colloidal lipid particles. Biomaterials 24:4283-300.
6. Hurley MJ, Jenner P. (2006). What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 111:715-28.
7. Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1-18.
8. Jain SA, Chauk DS, Mahajan HS, et al. (2009). Formulation and evaluation of nasal mucoadhesive microspheres of Sumatriptan succinate. J Microencapsul 26:711-21.
9. Lee PI. (1985). Kinetics of drug release from hydrogel matrices. J Control Release 2:277-88.
10. Mahajan HS, Tatiya BV, Nerkar PP. (2012). Ondansetron loaded pectin based microspheres for nasal administration: in vitro and in vivo studies. Powder Technol 221:168-76.
11. Mehnert W, Mader K. (2001). Solid lipid nanoparticles Production, characterization and applications. Adv Drug Deliv Rev 47:165-96.
12. Mistry A, Stolnik S, Illum L. (2009). Nanoparticles for direct nose-tobrain delivery of drugs. Int J Pharm 379:146-57.
13. Motwani SK, Chopra S, Talegaonkar S, et al. (2007). Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterisation. Eur J Pharm Biopharm 68:513-25.
14. Mukherjee S, Ray S, Thakur RS. (2009). Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Ind J Pharm Sci 71:349-58.
15. Paliwal R, Rai S, Vaidya B, et al. (2009). Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5:184-91.
16. Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR. (2011). Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J Microencapsul 29:103-14.
17. Patel S, Chavhan S, Soni H, et al. (2011). Brain targeting of risperidoneloaded solid lipid nanoparticles by intranasal route. J Drug Target 19:468-74.
18. Rudra A, Rudra P, Chatterjee S, et al. (2007). Parkinson's diseases and Anaesthesia. Ind J Anaesthesia 51:382-8.
19. Salawu F, Olokoba A, Danburam A. (2010). Current management of Parkinson's disease. Ann Afr Med 9:55-61.
20. Shegokar R, Singh KK, Muller RH. (2010). Production & stability of stavudine solid lipid nanoparticles - from lab to industrial scale. Int J Pharm. 416:461-70.
21. Tan SW, Billa N, Roberts CR, Berley JC. (2010). Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids Surf A: Physicochem Eng Asp 372:73-9.
22. Tas C, Ozkan CK, Savaser A, et al. (2006). Nasal absorption of metoclopramide from different Carbopol 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 64:246-54.
23. Trotta M, Debernardi F, Caputo O. (2003). Preparation of solid lipid nanoparticles by a solvent emulsiEcation-diffusion technique. Int J Pharm 257:153-60.
24. Varshosaz J, Tabbakhian M, Mohammadi MY. (2010). Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 20:286-96.
25. Venkateswarlu V, Manjunath K. (2004). Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95:627-38.
26. Vogel HG, ed. (2002). Psychotropic and neurotropic activity. In: Drug discovery and evaluation: pharmacological assays. 2nd ed. New York (NY): Springer, 577-81.
27. Wang Q, Gong T, Sun X, Zhang Z. (2011). Structural characterization of novel phospholipid lipid nanoparticles for controlled drug delivery. Colloids Surf B: Biointerfaces 84:406-12.
28. Zhang X, Liu J, Qiao H, et al. (2010). Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 197:120-8.